Synapse

← Gordon B. Mills

Papers by Gordon B. Mills

Page 8 · newest first

  1. The rise of genomic profiling in ovarian cancerExpert Review of Molecular Diagnostics · 2016
  2. Next-Generation Sequencing and Result Interpretation in Clinical Oncology: Challenges of Personalized Cancer TherapyAnnual Review of Medicine · 2016
  3. Role of RPL39 in Metaplastic Breast CancerJNCI Journal of the National Cancer Institute · 2016
  4. Clinical outcomes based on multigene profiling in metastatic breast cancer patientsOncotarget · 2016
  5. Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4–NDRG1 AxisCancer Research · 2016
  6. Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation setBMC Medicine · 2016
  7. ERK and p38 MAPK Activities Determine Sensitivity to PI3K/mTOR Inhibition via Regulation of MYC and YAPCancer Research · 2016
  8. Transgenic Expression of the Mitochondrial Chaperone TNFR-associated Protein 1 (TRAP1) Accelerates Prostate Cancer DevelopmentJournal of Biological Chemistry · 2016
  9. AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic MalignanciesMolecular Cancer Therapeutics · 2016
  10. Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel TherapeuticsClinical Cancer Research · 2016
  11. Integrated Patient-Derived Models Delineate Individualized Therapeutic Vulnerabilities of Pancreatic CancerCell Reports · 2016
  12. Cardiac glycosides display selective efficacy for STK11 mutant lung cancerScientific Reports · 2016
  13. Analysis of phosphatases in ER-negative breast cancers identifies DUSP4 as a critical regulator of growth and invasionBreast Cancer Research and Treatment · 2016
  14. Metabolic clusters of breast cancer in relation to gene- and protein expression subtypesCancer & Metabolism · 2016
  15. Patient derived mutation W257G of PPP2R1A enhances cancer cell migration through SRC-JNK-c-Jun pathwayScientific Reports · 2016
  16. Hotspot mutations delineating diverse mutational signatures and biological utilities across cancer typesBMC Genomics · 2016
  17. Rab25 acts as an oncogene in luminal B breast cancer and is causally associated with Snail driven EMTOncotarget · 2016
  18. BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics SystemMolecular Cancer Therapeutics · 2016
  19. Loss of ARID1A Activates ANXA1 , which Serves as a Predictive Biomarker for Trastuzumab ResistanceClinical Cancer Research · 2016
  20. High Intratumoral Stromal Content Defines Reactive Breast Cancer as a Low-risk Breast Cancer SubtypeClinical Cancer Research · 2016
  21. The management of malignant ascites and impact on quality of life outcomes in women with ovarian cancerExpert Review of Quality of Life in Cancer Care · 2016
  22. Direct Upregulation of STAT3 by MicroRNA-551b-3p Deregulates Growth and Metastasis of Ovarian CancerCell Reports · 2016
  23. Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitorsJournal of Clinical Investigation · 2016
  24. The degree of intratumor mutational heterogeneity varies by primary tumor sub-siteOncotarget · 2016
  25. Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast CancerClinical Cancer Research · 2016
  26. Rab11-FIP1C Is a Critical Negative Regulator in ErbB2-Mediated Mammary Tumor ProgressionENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) · 2016
  27. Cyclin E Associates with the Lipogenic Enzyme ATP-Citrate Lyase to Enable Malignant Growth of Breast Cancer CellsCancer Research · 2016
  28. Phosphatase PTP4A3 Promotes Triple-Negative Breast Cancer Growth and Predicts Poor Patient SurvivalCancer Research · 2016
  29. Inferring causal molecular networks: empirical assessment through a community-based effortNature Methods · 2016
  30. Targeting Therapeutic Liabilities Engendered by PIK3R1 Mutations for Cancer TreatmentPharmacogenomics · 2016
  31. Functional annotation of rare gene aberration drivers of pancreatic cancerNature Communications · 2016
  32. Genomic-Glycosylation Aberrations in Tumor Initiation, Progression and ManagementAIMS Medical Science · 2016
  33. Proteomic Characterization of Head and Neck Cancer Patient–Derived XenograftsMolecular Cancer Research · 2015
  34. Personalized Preclinical Trials in BRAF Inhibitor–Resistant Patient-Derived Xenograft Models Identify Second-Line Combination TherapiesClinical Cancer Research · 2015
  35. Mouse models of human PIK3CA-related brain overgrowth have acutely treatable epilepsyeLife · 2015
  36. Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare MutationsCancer Research · 2015
  37. Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering GlycolysisCell Reports · 2015
  38. Glucose starvation induces mutation and lineage-dependent adaptive responses in a large collection of cancer cell linesInternational Journal of Oncology · 2015
  39. mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast CancerClinical Cancer Research · 2015
  40. Large-Scale Drug Screens Support Precision MedicineCancer Discovery · 2015
  41. MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian CancerClinical Cancer Research · 2015
  42. Multigene Clinical Mutational Profiling of Breast Carcinoma Using Next-Generation SequencingAmerican Journal of Clinical Pathology · 2015
  43. A putative biomarker signature for clinically effective AKT inhibition: correlation of in vitro, in vivo and clinical data identifies the importance of modulation of the mTORC1 pathwayOncotarget · 2015
  44. Modulation of Breast Cancer Risk Biomarkers by High-Dose Omega-3 Fatty Acids: Phase II Pilot Study in Premenopausal WomenCancer Prevention Research · 2015
  45. Genome-wide perturbations by miRNAs map onto functional cellular pathways, identifying regulators of chromatin modifiersnpj Systems Biology and Applications · 2015
  46. Yes‐associated protein 1 and transcriptional coactivator with PDZ‐binding motif activate the mammalian target of rapamycin complex 1 pathway by regulating amino acid transporters in hepatocellular carcinomaHepatology · 2015
  47. Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient OutcomesPLoS ONE · 2015
  48. Myristoylation confers noncanonical AMPK functions in autophagy selectivity and mitochondrial surveillanceNature Communications · 2015
  49. Modulation of Breast Cancer Risk Biomarkers by High-Dose Omega-3 Fatty Acids: Phase II Pilot Study in Postmenopausal WomenCancer Prevention Research · 2015
  50. Regulation of the PI3K pathway through a p85α monomer–homodimer equilibriumeLife · 2015